FMP
NRx Pharmaceuticals, Inc.
NRXP
NASDAQ
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
1.53 USD
-0.04 (-2.61%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Jonathan C. Javitt M.D., M.P.H.
sector
Healthcare
industry
Biotechnology
website
https://www.nrxpharma.comexchange
NASDAQ
Description
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
CIK
0001719406
ISIN
US6294441000
CUSIP
089482103
Address
1201 Orange Street
Phone
484 254 6134
Country
US
Employee
2
IPO Date
Dec 4, 2017
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
NRXP Financial Summary
CIK
0001719406
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
089482103
ISIN
US6294441000
Country
US
Price
1.53
Beta
1.27
Volume Avg.
214k
Market Cap
18.5M
Shares
-
52-Week
1.1-7.33
DCF
-0.6
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.73
P/B
-
Website
https://www.nrxpharma.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest NRXP News
It looks like there's no news available.
